Join the club for FREE to access the whole archive and other member benefits.

Peter Marks

Peter Marks, M.D., Ph.D. is the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration

Dr. Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University. Following this, he completed an Internal Medicine residency and Hematology/Medical Oncology fellowship at Brigham and Women's Hospital in Boston, where he subsequently joined the attending staff as a clinician-scientist and eventually served as Clinical Director of Hematology.

He then moved on to work for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016.  Dr. Marks is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physicians.

Visit website: https://www.fda.gov/node/369162

See also: Company Food and Drug Administration (FDA) - Ensuring safety of drugs, medical supplies and food which is used daily.

Details last updated 17-Dec-2019

Peter Marks News

Some stem cell products are not FDA certified

Some stem cell products are not FDA certified

Medical News Today - 10-Dec-2019

US companies received a warning from the FDA for selling stem cell products without approval

FDA Target Rogue Gene Therapy Clinics

FDA Target Rogue Gene Therapy Clinics

New York Times - 16-Nov-2017

FDA issued new guidelines for expedited review of stem cell and gene therapies. Will crack down ...